Is Alectinib/Aletinib effective?

Alectinib/Alectinib (Alectinib) has shown good efficacy in the treatment of patients with ALK (tyrosine kinase)-positive advanced non-small cell lung cancer (NSCLC). As a targeted drug, alectinib inhibits the growth and spread of tumor cells by interfering with the abnormal activation of the ALK fusion gene, thereby improving the prognosis of patients. Alectinib/As a first-line treatment, Alectinib shows a higher tumor control rate and longer progression-free survival compared with traditional platinum-based chemotherapy regimens. Clinical trial results show that alectinib can effectively inhibit the proliferation and spread of tumor cells and shrink or stabilize tumors.